[Lanzoptol efficacy at gastroesophageal reflux disease: results of multicenter study leader].
Lazebnik
L B
LB
Bordin
D S
DS
Masharova
A A
AA
V'iuchnova
E S
ES
Zakharova
N V
NV
Abdulkhakov
R A
RA
Prokhorova
L V
LV
Nikolaeva
N N
NN
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D016145:Endoscopy, Digestive System; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D064747:Lansoprazole